Precision BioSciences Posts 28-Cent Loss, Beats Estimates by Wide Margin
DTIL has more than doubled off its 52-week low of $3.53.
Summary
Precision BioSciences reported a Q3 adjusted loss of 28 cents per share, far narrower than the 85-cent loss five analysts expected and a big improvement from the $1.84 loss a year earlier. Revenue was zero versus the $1.10M analysts modeled, so the beat is cost-driven, not commercial. The $7.59M quarterly net loss was flattered by a $12.7M non-cash warrant remeasurement gain disclosed in the 10-Q filed this morning, which also showed $108.0M of cash and runway guided through 2028. Shares are up 67.1% year to date and 11.0% this quarter heading into the print, and the Street still carries a strong buy consensus with a $20 median target. The zero-revenue line keeps the story about cash burn and the PBGENE-DMD Phase 1/2 program, where the first patient was dosed in August.
At the time of this announcement, DTIL was trading at $7.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.8M. The 52-week trading range was $3.53 to $9.62. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.